Drugs like Ozempic (GLP-1 agonists) show promise for addiction treatment because they may reduce the fundamental 'wanting' of a substance, rather than just helping a person fight cravings. An addicted patient's core desire is often 'not to want,' and these drugs may directly address that by altering the brain's reward and satiety signaling.

GLP-1 drugs like Ozempic affect more than just appetite; they broadly dampen the brain's dopamine-driven reward system. This biochemical change can reduce the pleasure derived from relationships and social activities, leading to emotional flattening and the breakdown of romantic partnerships, a phenomenon dubbed the "Ozempic divorce."

While AI dominates headlines, GLP-1 drugs could have a more profound and immediate impact on society. They address the core mechanism of desire ("wanting less"), with applications for obesity, addiction, and compulsive behaviors that could fundamentally reshape public health and daily life.

Beyond direct physiological changes, GLP-1s help correct underlying physiology, which restores the mental and physical resources needed to maintain fundamentals like sleep, exercise, and nutrition. This secondary effect can be more profound than the drug's primary action.

The satiation signal from GLP-1s to the brain stem also down-regulates dopamine and the desire for it. This explains anecdotal reports and active studies on their effect in reducing cravings for nicotine, alcohol, shopping, and gambling.

GLP-1s are more than weight-loss aids; they are powerful anti-inflammatory agents affecting cardiovascular and neurological health. They even reduce cravings for things like gambling and cigarettes, acting as systemic moderators for entire biological systems, not just appetite.

Our evolutionary instincts for craving scarce resources haven't adapted to the modern world of abundance. GLP-1 drugs provide a biological support system, or "scaffolding," that helps regulate these outdated cravings for things like high-calorie food and other hedonic activities.

GLP-1 agonists don't just reduce cravings for food; they suppress wanting and desire in general. Because romantic love operates on the same dopaminergic pathways, these 'anti-desire' drugs may significantly diminish a person's capacity to fall in love or maintain romantic feelings in existing relationships.

GLP-1 agonists not only reduce hunger but also curb addictive behaviors like gambling. This suggests they impact the brain's fundamental reward systems, which could inadvertently blunt the risk-taking appetite essential for roles like entrepreneurship.